CIK 0001651308 · Large accelerated filer
BeOne Medicines Ltd.
Sign in to watch- Ticker
- BEIGF
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 981209416
- Phone
- 41-616851900
- Business address
- C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, Switzerland, 4051
- Former names
- BeiGene, Ltd.
Securities
- ONC American Depositary Shares Nasdaq
- BEIGF Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $48,487,541
- in 9 filings, $47.8M under 10b5-1 plans
Net −$48,487,541. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-04 | Lee Chan Henry SVP, General Counsel | Option exercise 10b5-1 | +502 | $194.47 | $98K | 502 |
| 2026-02-04 | Lee Chan Henry SVP, General Counsel | Option exercise 10b5-1 | +662 | $213.32 | $141K | 1,164 |
| 2026-02-04 | Lee Chan Henry SVP, General Counsel | Option exercise 10b5-1 | +496 | $159.03 | $79K | 1,660 |
| 2026-02-04 | Lee Chan Henry SVP, General Counsel | Sale 10b5-1 | −664 | $348.79 | $232K | 996 |
| 2026-02-04 | Lee Chan Henry SVP, General Counsel | Sale 10b5-1 | −996 | $350.00 | $349K | 0 |
| 2026-02-04 | Lee Chan Henry SVP, General Counsel | Option exercise · Share Option (Right to Buy) 10b5-1 | −6,526 | 23,920 | ||
| 2026-02-04 | Lee Chan Henry SVP, General Counsel | Option exercise · Share Option (Right to Buy) 10b5-1 | −8,606 | 88,413 | ||
| 2026-02-04 | Lee Chan Henry SVP, General Counsel | Option exercise · Share Option (Right to Buy) 10b5-1 | −6,448 | 111,670 | ||
| 2026-01-07 | Lee Chan Henry SVP, General Counsel | Option exercise 10b5-1 | +202 | $194.47 | $39K | 202 |
| 2026-01-07 | Lee Chan Henry SVP, General Counsel | Option exercise 10b5-1 | +266 | $213.32 | $57K | 468 |
| 2026-01-07 | Lee Chan Henry SVP, General Counsel | Option exercise 10b5-1 | +196 | $159.03 | $31K | 664 |
| 2026-01-07 | Lee Chan Henry SVP, General Counsel | Sale 10b5-1 | −664 | $331.76 | $220K | 0 |
| 2026-01-07 | Lee Chan Henry SVP, General Counsel | Option exercise · Share Option (Right to Buy) 10b5-1 | −2,626 | 30,446 | ||
| 2026-01-07 | Lee Chan Henry SVP, General Counsel | Option exercise · Share Option (Right to Buy) 10b5-1 | −3,458 | 97,019 | ||
| 2026-01-07 | Lee Chan Henry SVP, General Counsel | Option exercise · Share Option (Right to Buy) 10b5-1 | −2,548 | 118,118 | ||
| 2025-12-31 | Wang Lai President, Global Head of R&D | Grant or award | +427,895 | 1,451,424 | ||
| 2025-12-16 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −1,877 | $300.80 | $565K | 22,492 |
| 2025-12-16 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −600 | $300.98 | $181K | 21,892 |
| 2025-12-16 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −2,567 | $301.79 | $775K | 19,325 |
| 2025-12-16 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −1,512 | $302.31 | $457K | 17,813 |
Page 15 of 71 · 1,406 trades